Topical corticosteroids, such as beclomethasone dipropionate, budesonide, triamcinolone acetonide, flunisolide, ciclesonide, mometasone furoate (MF), fluticasone propionate (FP), and fluticasone furoate (FF) are first-line treatments for upper respiratory allergic conditions such as asthma and seasonal/perennial rhinitis, as they provide local efficacy and, thereby, reduce systemic glucocorticoid exposure \[[@B1]-[@B4]\]. In recent literature, comparative relative receptor affinity (RRA) values for glucocorticoid receptors in nasal/lung tissue are increasingly used to differentiate among topical corticosteroids. In many instances, the presentation of RRA data and rank ordering of compounds is accompanied by overt or subtle implications of clinical efficacy ramifications. While RRA has a rightful place in the comparison of *in vitro*potency of corticosteroids, practicing clinicians need to understand the limitations of such data when they are used as arguments for the clinical efficacy of a given glucocorticoid.

As a case in point, I refer to a recent publication in *Respiratory Research*(2007:8:54) in which Valotis and Högger report data comparing the glucocorticoid-receptor and lung-tissue binding affinities of FF, FP, and MF \[[@B5]\] While the methodology of the study and the resulting data are sound, the authors imply, that a high receptor affinity, such as the one reported in this publication for FF, improves the local efficacy of a topical glucocorticoid (see Background section of the article) and that the high relative receptor affinity of the \"enhanced-affinity\" FF \"that exceeds the RRAs of all other clinically used glucocorticoids\" \"may contribute to a highly efficacious profile for FF\". To be fair, Högger\'s group is not the only one confusing potency and efficacy of inhaled glucocorticoids, as the interchangeable use of the two terms can be found throughout the literature, often with the underlying assumption that a high affinity glucocorticoid must be the better one. The clinical and pharmacologic reality, however, is that \"potency\" and \"efficacy\" are not interchangeable terms and that differences in the receptor affinity do not necessarily translate into differences in local or clinical efficacy. It only indicates that for a \"weaker\" glucocorticoid, higher concentrations at the site of action are necessary to achieve the same pharmacodynamic effect. In the clinical setting, differences in potency, therefore can be overcome by adjusting the dose \[[@B6]\]. Therefore, two glucocorticoids that differ only in the receptor binding affinity (e.g. by 25%) would show the same clinical efficacy and systemic side effects when the \"weaker\" steroid is given at a 25% higher dose.

In summary, while it is not my intent to discredit the importance of studying RRA, I am recommending caution in the interpretation of and reliance on such data, particularly when claims of clinical distinction are drawn. As recent pharmacokinetic/pharmacodynamic evaluations have shown, the topical selectivity and local targeting of glucocorticoids is independent of the binding affinity and solely determined by pharmacokinetic properties \[[@B7]\].
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